Deodorant or Antiperspirant: Which One Needs a Drug Filing

Someone asks whether their new underarm product needs a CNF or something heavier, and the honest answer is: it depends on one specific claim, not on the ingredient list alone. This trips up a lot of first-time founders who assume "underarm product" is one regulatory category.

The line is drawn at sweat reduction, not odor control

A deodorant that masks or reduces odor is a cosmetic. It gets notified through the standard Cosmetic Notification Form process, same as any other cosmetic, within 10 days of first sale.

An antiperspirant that reduces perspiration itself, typically through an aluminum-based active, is treated as a drug, not a cosmetic. Antiperspirant, along with sunscreen, anti-acne, anti-dandruff, and fluoride toothpaste products, sits in drug territory because the product is making a physiological claim (stopping or reducing a bodily function) rather than a purely cosmetic claim (masking odor, conditioning skin).

Why this catches people off guard

It's tempting to think the ingredient itself is what decides the category, since aluminum compounds are the active ingredient people associate with "real" antiperspirants. But the more precise trigger is the claim you make and the mechanism the product is actually designed around. If your product contains an aluminum compound specifically to reduce sweat and you market it that way, that's an antiperspirant claim, and antiperspirants are regulated as drugs, not cosmetics, in the Canadian framework.

A few scenarios to think through:

• A deodorant with odor-neutralizing ingredients and no sweat-reduction claim: cosmetic, CNF required
• A product containing an aluminum salt marketed to "stop sweat" or "reduce perspiration": functions as an antiperspirant, drug territory
• A "natural deodorant" that happens to contain a small amount of an ingredient with some antiperspirant-like property, marketed purely on odor control: this is exactly the gray area where your actual claims language matters more than the ingredient list, and it's worth getting a second opinion rather than guessing

Check your own marketing copy, not just your formula

This is the practical takeaway: read your packaging and website copy the way a regulator would, independent of what you know about your own formula. Words like "stops sweat," "reduces perspiration," or "keeps you dry" point toward an antiperspirant claim. Words like "neutralizes odor," "freshens," or "keeps you feeling clean" stay in cosmetic territory. It's entirely possible to have a formula that could support either framing, and the claim you choose to print is what determines which regulatory path you're on.

Product type	Core claim	Category	Filing path
Deodorant	Masks or reduces odor	Cosmetic	CNF within 10 days of first sale
Antiperspirant	Reduces or stops perspiration	Drug	Drug regulatory pathway, not CNF
Ambiguous "sweat control" copy	Depends on actual wording and mechanism	Needs a closer look	Verify before you print packaging

If you're genuinely unsure

Don't guess based on what similar products on the shelf seem to do. Read your own draft packaging copy line by line and ask whether any phrase implies sweat reduction rather than odor management. If your formula includes an aluminum-based ingredient specifically for its antiperspirant effect, treat the product as a drug from the start rather than filing it as a cosmetic and hoping the claim language covers you. When it's genuinely unclear which side of the line you're on, that's worth a direct check with the current Health Canada guidance rather than an assumption carried over from a US or EU product you've seen.

Cosmetic Comply is built for the cosmetic side of this line, deodorants included. If your product is a straightforward odor-control formula, it screens the ingredients, checks them against the Hotlist and the fragrance allergen thresholds, and files the CNF once everything checks out. If your claims start drifting into sweat-reduction territory, that's the signal to pause and confirm you're not actually building a drug product before you file it as anything else.